Resistance in the land of molecular cancer therapeutics
- 1 August 2002
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 2 (2), 99-102
- https://doi.org/10.1016/s1535-6108(02)00101-0
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Perspectives on the development of a molecularly targeted agentCancer Cell, 2002
- Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemiaCancer Cell, 2002
- α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571Blood, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Role of alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571JNCI Journal of the National Cancer Institute, 2000
- Reversibility of acute B-cell leukaemia induced by BCR–ABL1Nature Genetics, 2000
- Reversible Tumorigenesis by MYC in Hematopoietic LineagesMolecular Cell, 1999
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990